Elizabeth Crouch, Nick Yell, Laura Herbert, Teri Browne, Peiyin Hung
INTRODUCTION: Rural areas face significant disparities in dialysis care compared to urban areas due to limited access to dialysis facilities, longer travel distances, and a shortage of healthcare professionals. The objective of this study is to conduct a national examination of rural-urban differences in quality of dialysis care offered across counties in the U.S. METHODS: Data was gathered from Medicare-certified dialysis facilities in 2020 from the Centers for Medicare & Medicaid Services website...
February 11, 2024: American Journal of Nephrology
Hongyun Wang, Hongyan Liu, Hong Cheng, Xue Xue, Yamei Ge, Xiaoqin Wang, Jun Yuan
INTRODUCTION: To explore the renoprotective effects of Klotho on podocyte injury mediated by complement activation and autoantibodies in idiopathic membranous nephropathy (IMN). METHODS: Rat passive Heymann nephritis (PHN) was induced as an IMN model. Urine protein levels, serum biochemistry, kidney histology, and podocyte marker levels were assessed. In vitro, sublytic podocyte injury was induced by C5b-9. The expression of Klotho, transient receptor potential channel 6 (TRPC6), and cathepsin L (CatL); its substrate synaptopodin; and the intracellular Ca2+ concentration were detected via immunofluorescence...
February 8, 2024: American Journal of Nephrology
Mayuko Hori, Hiroshi Takahashi, Chika Kondo, Fumihito Hayashi, Shigehiro Tokoroyama, Yoshiko Mori, Makoto Tsujita, Yuichi Shirasawa, Asami Takeda, Kunio Morozumi, Shoichi Maruyama
INTRODUCTION: Sarcopenia and vitamin D deficiency are highly prevalent among patients undergoing haemodialysis. Although vitamin D deficiency, assessed using serum 25-hydroxyvitamin D (25(OH)D) levels, is known to be associated with sarcopenia in the general population, whether serum 25(OH)D levels are associated with sarcopenia in patients undergoing haemodialysis with suppressed renal activation of 25(OH)D remains unclear. This study aimed to examine the association between serum 25(OH)D levels and sarcopenia in patients undergoing haemodialysis...
February 2, 2024: American Journal of Nephrology
Steven Fishbane, Deborah J Clegg, Edgar V Lerma, Anjay Rastogi, Jeffrey Budden, Isabelle Morin, Warren Wen, Frédérique Menzaghi, Joel Topf
Black and African American (AA) people are over-represented in the kidney failure population; therefore, the safety and efficacy of difelikefalin in Black/AA patients was evaluated. This was a post hoc, pooled exploratory subgroup analysis of the Phase 3 KALM-1 and -2 studies. Patients undergoing hemodialysis (HD) who had moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) at enrollment were stratified into self-reported Black/AA or White subgroups. Patients were randomized (1:1) to receive intravenous (IV) difelikefalin 0...
January 22, 2024: American Journal of Nephrology
(no author information available yet)
No abstract text is available yet for this article.
January 19, 2024: American Journal of Nephrology
Dan Zhao, Wei Wang, Yang-Yang Niu, Xi-Hui Ren, Ai-Jun Shen, Yong-Sheng Xiang, Hong-Yan Xie, Le-Hao Wu, Yu Chen, Ying-Ying Zhang
BACKGROUND: Renal fibrosis (RF) being the most important pathological change in the progression of CKD, is currently assessed by the evaluation of a biopsy. This present study aimed to apply a novel functional MRI (fMRI) protocol named amide proton transfer weighting (APTw) to evaluate RF non-invasively. METHODS: Male Sprague-Dawley (SD) rats were initially subjected to bilateral kidney ischemia/reperfusion injury (IRI), unilateral ureteral obstruction (UUO) and Sham operation, respectively...
January 16, 2024: American Journal of Nephrology
Hui-Yun Jung, Jung-Hwa Ryu, Myung-Gyu Kim, Kyu Ha Huh, Kyo Won Lee, Hee-Yeon Jung, Kyung Pyo Kang, Han Ro, Seungyeup Han, Jaeseok Yang
INTRODUCTION: Serum activin A has been reported to contribute to vascular calcification and kidney fibrosis in chronic kidney disease. We aimed to investigate whether higher serum activin levels were associated with poor allograft outcomes in patients with kidney transplants (KT). METHODS: A total of 860 KT patients from KNOW-KT (KoreaN cohort study for Outcome in patients With Kidney Transplantation) were analyzed. We measured serum activin levels at pre-KT and 1 year after KT...
January 10, 2024: American Journal of Nephrology
Aurora Pérez-Gómez, Lucie Fernandez, Joost P Schanstra, Julie Klein
No abstract text is available yet for this article.
January 10, 2024: American Journal of Nephrology
Hamad Ali, Barrak Alahmad, Sarah R Senum, Samia Warsame, Yousif Bahbahani, Mohamed Abu-Farha, Jehad Abubaker, Malak Alqaddoumi, Fahd Al-Mulla, Peter C Harris
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic disease characterized by the accumulation of fluid-filled cysts in the kidneys, leading to renal volume enlargement and progressive kidney function impairment. Disease severity, though, may vary due to allelic and genetic heterogeneity. This study aimed to determine genotype-phenotype correlations between PKD1 truncating and non-truncating mutations and kidney function decline in ADPKD patients. METHODS: We established a single center retrospective cohort study in Kuwait where we followed every patient with a confirmed PKD1-ADPKD diagnosis clinically and genetically...
January 9, 2024: American Journal of Nephrology
Mairead Pfaff, Michelle R Denburg, Kevin E Meyers, Tammy M Brady, Mary B Leonard, Andrew N Hoofnagle, Christine B Sethna
INTRODUCTION: Fibroblast growth factor 23 (FGF23) has direct effects on the vasculature and myocardium, and high levels of FGF23 are a risk factor for cardiovascular disease (CVD); however, the impact of FGF23 on CVD in primary proteinuric glomerulopathies has not been addressed. METHODS: The associations of baseline plasma intact FGF23 levels with resting blood pressure (BP) and lipids over time among adults and children with proteinuric glomerulopathies enrolled in the Nephrotic Syndrome Study Network (NEPTUNE) were analyzed using generalized estimating equation regression analyses...
2024: American Journal of Nephrology
Juan A Medaura, Meijiao Zhou, Linda H Ficociello, Michael S Anger, Stuart M Sprague
INTRODUCTION: Sucroferric oxyhydroxide (SO), a non-calcium, chewable, iron-based phosphate binder (PB), effectively lowers serum phosphorus (sP) concentrations while reducing pill burden relative to other PBs. To date, SO studies have largely examined treatment-experienced, prevalent hemodialysis populations. We aimed to explore the role of first-line SO initiated during the first year of dialysis. METHODS: We retrospectively analyzed deidentified data from adults receiving in-center hemodialysis who were prescribed SO monotherapy within the first year of hemodialysis as part of routine clinical care...
2024: American Journal of Nephrology
Lan Lan, Yuxin Lin, Binfeng Yu, Yin Wang, Hong Pan, Huijing Wang, Xiaowei Lou, Xiabing Lang, Qiankun Zhang, Lie Jin, Yi Yang, Liang Xiao, Jianghua Chen, Fei Han
INTRODUCTION: Rituximab has been proven effective and safe in pediatric patients with frequently relapsing or steroid-dependent nephrotic syndrome (FR/SDNS). We aimed to analyze the efficacy and safety of rituximab in adult FR/SDNS patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). METHODS: A retrospective cohort study at three nephrology centers in China included adult FR/SDNS patients with biopsy-proven MCD or FSGS. Primary outcomes were relapse frequency and first relapse-free survival time...
2024: American Journal of Nephrology
Li Qin Gao, Can Can Xue, Jing Cui, Jie Xu, Chun Zhang, Dong Ning Chen, Jost B Jonas, Ya Xing Wang
INTRODUCTION: The aim of the study was to investigate associations between diabetic retinopathy (DR) and chronic kidney disease (CKD) in patients with type 2 diabetes (TD2). METHODS: The participants of the cross-sectional, community-based Tongren Health Care Study underwent a detailed medical and ophthalmological examination. We defined TD2 by a fasting plasma glucose concentration of ≥7.0 mmol/L or a medical history. CKD was classified as either reduced estimated glomerular filtration rate (eGFR) of <60 mL/min/1...
2024: American Journal of Nephrology
Akio Nakashima, Yoshia Miyawaki, Hirotaka Komaba, Noriaki Kurita, Yoshihiro Onishi, Takashi Yokoo, Masafumi Fukagawa
INTRODUCTION: Hyporesponsiveness to erythropoiesis stimulating agents (ESAs) is important problem in dialysis patients. While proton pump inhibitors (PPIs) may inhibit iron absorption, few studies have examined associations between PPIs and ESA-resistant anemia in hemodialysis patients. This study examined the associations between PPIs and ESA-resistant anemia in hemodialysis patients. METHODS: The present study was a cross-sectional study using repeated 4-month observations, up to eight observations/patient, from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS)...
2024: American Journal of Nephrology
Rima S Zahr, Santosh L Saraf
BACKGROUND: Sickle cell disease is an inherited red blood cell disorder that affects approximately 100,000 people in the USA and 25 million people worldwide. Vaso-occlusion and chronic hemolysis lead to dysfunction of vital organ systems, with the kidneys being among the most commonly affected organs. SUMMARY: Early renal manifestations include medullary ischemia with the loss of urine-concentrating ability and hyperfiltration. This can be followed by progressive damage characterized by persistent albuminuria and a decline in the estimated glomerular filtration rate...
2024: American Journal of Nephrology
Chen-Yi Yuan, Yuan-Cheng Gao, Yi Lin, Lin Liu, Xiao-Gang Shen, Wen-Li Zou, Min-Min Wang, Quan-Quan Shen, Li-Na Shao, Yue-Ming Liu, Jia-Wei Zhang, Zhi-Hui Pan, Yan Zhu, Jing-Ting Yu, Xu-Guang Yu, Bin Zhu
BACKGROUND: Mineralocorticoid receptor blockade could be a potential approach for the inhibition of chronic kidney disease (CKD) progression. The benefits and harms of different mineralocorticoid receptor antagonists (MRAs) in CKD are inconsistent. OBJECTIVES: The aim of the study was to summarize the benefits and harms of MRAs for CKD patients. METHODS: We searched MEDLINE, EMBASE, and the Cochrane databases for trials assessing the effects of MRAs on non-dialysis-dependent CKD populations...
2024: American Journal of Nephrology
Caroline W H de Fijter, Joanna Stachowska-Pietka, Jacek Waniewski, Bengt Lindholm
Recently, hyperosmolar hyponatremia following excessive off-label use of two exchanges of 2 L icodextrin daily during peritoneal dialysis (PD) was reported. We encountered a cluster of 3 cases of PD patients who developed hyperosmolar hyponatremia during on-label use of icodextrin. This appeared to be due to absorption of icodextrin since after stopping icodextrin, the serum sodium level and osmol gap returned to normal, while a rechallenge again resulted in hyperosmolar hyponatremia. We excluded higher than usual concentrations of specific fractions of dextrins in fresh icodextrin dialysis fluid (lot numbers of used batches were checked by manufacturer)...
2024: American Journal of Nephrology
Joyce Xia, Alice J Tan, Bianca Biglione, Bethany Cucka, Lauren Ko, Emily D Nguyen, Charbel C Khoury, Malcolm K Robinson, Sagar U Nigwekar, Daniela Kroshinsky
Nephrogenic calciphylaxis is associated with multiple risk factors including long-term dialysis dependence, hyperphosphatemia, hypercalcemia, parathyroid hormone derangements, vitamin K deficiency, obesity, diabetes mellitus, warfarin use, and female sex. Bariatric surgery is known to cause altered absorption, leading to mineral and hormonal abnormalities in addition to nutritional deficiency. Prior case reports on calciphylaxis development following bariatric surgery have been published, though are limited in number...
2024: American Journal of Nephrology
Milton Packer
Renal anemia is treated with erythropoiesis-stimulating agents (ESAs), even though epoetin alfa and darbepoetin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed as an alternative to ESAs, producing comparable increases in hemoglobin. However, in advanced chronic kidney disease, HIF-PHD inhibitors can increase the risk of cardiovascular death, heart failure, and thrombotic events to a greater extent than that with ESAs, indicating that there is a compelling need for safer alternatives...
2024: American Journal of Nephrology
Valerie A Luyckx, Ayah Elmaghrabi, Manisha Sahay, Nicole Scholes-Robertson, Laura Sola, Tobias Speare, Elliot K Tannor, Katherine Tuttle, Ikechi G Okpechi
Chronic kidney disease (CKD) is an important but insufficiently recognized public health problem. Unprecedented advances in delaying progression of CKD and reducing kidney failure and death have been made in recent years, with the addition of the sodium glucose co-transporter 2 inhibitors and other newer medication to the established standard of care with inhibitors of the renin angiotensin system. Despite knowledge of these effective therapies, their prescription and use remains suboptimal globally, and more specially in low resource settings...
December 18, 2023: American Journal of Nephrology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.